Aprajita Mattoo

Aprajita Mattoo

Auto-generated profile, based on publicly available information

Aprajita Mattoo

Department of Surgery NYU Langone Health New York New York USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2025 in American Journal of Transplantation
Verified
Journal Article
Closed access
MLMacey L. Levan
Macey L. Levan
HAHarsimar Kaur Ahuja
Harsimar Kaur Ahuja
RRRhiannon D. Reed
Rhiannon D. Reed
JLJayme Locke
Jayme Locke
CSCarolyn N. Sidoti
Carolyn N. Sidoti
WWWinfred Williams
Winfred Williams

16 April 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
VTVasishta S. Tatapudi
Vasishta S. Tatapudi
AMAprajita Mattoo
Aprajita Mattoo
TSTamar Schiff
Tamar Schiff
SMSapna A. Mehta
Sapna A. Mehta
ESEdward Y. Skolnik
Edward Y. Skolnik
RMRobert A. Montgomery
Robert A. Montgomery
The scarcity of transplantable organs represents a worldwide public health crisis, and as a result, thousands of people with kidney failure die waiting for a transplant each year. Xenotransplantation involves transplanting organs from an animal source into humans, offering a potential solution to this significant unmet need. Indeed, if there is a limitless supply of organs, many more patients who do not meet the current criteria for transplant eligibility could also be considered as candidates. Although there are examples of attempts to transplant animal tissues or organs into humans dating back over 300 years, none were successful due to cross-species immunologic incompatibility. Even so, significant advances in genetic engineering and the emergence of novel immunosuppressive agents have spurred impressive improvements in xenograft survival in preclinical studies involving nonhuman primates. Furthermore, recent reports of genetically modified pig kidney and heart xenotransplants in human decedents and living recipients on a compassionate use basis have provided impetus to advancing the field toward first-in-human trials. However, studies in nonhuman primates and humans thus far have described adaptive as well as innate immune-mediated xenograft injury. Understanding the mechanistic aspects of these responses at the cellular and molecular levels is critical to the development of targeted genetic modifications and innovative therapeutic strategies aimed at preventing rejection and inducing tolerance. Moreover, the physiologic components of the bidirectional communication between the human host and pig xenograft must also be understood and manipulated. Here, we review the breakthroughs in kidney xenotransplantation in the past few decades and highlight the immunologic hurdles that have yet to be overcome.

27 May 2026 in Clinical Transplantation
Verified
Journal Article
Closed access
MLMacey L. Levan
Macey L. Levan
AMAprajita Mattoo
Aprajita Mattoo
SHSyed Ali Husain
Syed Ali Husain
BLBonnie E. Lonze
Bonnie E. Lonze
JSJeffrey M. Stern
Jeffrey M. Stern
AMAllan B. Massie
Allan B. Massie